XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock
 [1]
Preferred A Stock
Additional Paid-In Capital
 [1]
Accumulated Deficit
Total Stockholders’ Equity attributable to Agrify
Non- Controlling Interests
Total
Balance at Dec. 31, 2020 $ 19,831 $ (26,510) $ (6,679) $ 225 $ (6,454)
Balance (in Shares) at Dec. 31, 2020 21,058 100,000          
Stock-based compensation 2,135 2,135 2,135
Beneficial conversion feature associated with amended Convertible Promissory Notes 3,869 3,869 3,869
Conversion of Convertible Notes 13,100 13,100 13,100
Conversion of Convertible Notes (in Shares) 8,485          
Issuance of Common Stock – Initial Public Offering (“IPO”), net of fees 56,961 56,961 56,961
Issuance of Common Stock – Initial Public Offering (“IPO”), net of fees (in Shares) 31,050          
Issuance of Common Stock – Secondary public offering, net of fees 79,839 79,839 79,839
Issuance of Common Stock – Secondary public offering, net of fees (in Shares) 31,945          
Conversion of Preferred A Stock
Conversion of Preferred A Stock (in Shares) 6,865 (100,000)          
Exercise of options 439 439 439
Exercise of options (in Shares) 872          
Exercise of warrants 5 5 5
Exercise of warrants (in Shares) 1,201          
Net loss (3,810) (3,810) (33) (3,843)
Balance at Mar. 31, 2021 176,179 (30,320) 145,859 192 146,051
Balance (in Shares) at Mar. 31, 2021 101,476          
Balance at Dec. 31, 2020 19,831 (26,510) (6,679) 225 (6,454)
Balance (in Shares) at Dec. 31, 2020 21,058 100,000          
Net loss             (9,279)
Balance at Jun. 30, 2021 177,392 (35,956) 141,436 392 141,828
Balance (in Shares) at Jun. 30, 2021 101,869          
Balance at Dec. 31, 2020 19,831 (26,510) (6,679) 225 (6,454)
Balance (in Shares) at Dec. 31, 2020 21,058 100,000          
Balance at Dec. 31, 2021 196,034 (58,975) 137,059 365 137,424
Balance (in Shares) at Dec. 31, 2021 111,035          
Balance at Mar. 31, 2021 176,179 (30,320) 145,859 192 146,051
Balance (in Shares) at Mar. 31, 2021 101,476          
Stock-based compensation 931 931 931
Exercise of options 282 282 282
Exercise of options (in Shares) 393          
Net loss (5,636) (5,636) 200 (5,436)
Balance at Jun. 30, 2021 177,392 (35,956) 141,436 392 141,828
Balance (in Shares) at Jun. 30, 2021 101,869          
Balance at Dec. 31, 2021 196,034 (58,975) 137,059 365 137,424
Balance (in Shares) at Dec. 31, 2021 111,035          
Stock-based compensation 953 953 953
Issuance of Common Stock and warrants in private placement 14,800 14,800 14,800
Issuance of Common Stock and warrants in private placement (in Shares) 12,252          
Issuance of debt and warrants in private placement
Acquisition of Lab Society 1,903 1,903 1,903
Acquisition of Lab Society (in Shares) 1,490          
Exercise of options 10 10 10
Exercise of options (in Shares) 21          
Exercise of warrants 1 1 1
Exercise of warrants (in Shares) 7,916          
Net loss 1,780 1,780 1 1,781
Balance at Mar. 31, 2022 213,701 (57,195) 156,506 366 156,872
Balance (in Shares) at Mar. 31, 2022 132,714          
Balance at Dec. 31, 2021 196,034 (58,975) 137,059 365 137,424
Balance (in Shares) at Dec. 31, 2021 111,035          
Net loss             (72,820)
Balance at Jun. 30, 2022 214,652 (131,799) 82,853 369 83,222
Balance (in Shares) at Jun. 30, 2022 132,957          
Balance at Mar. 31, 2022 213,701 (57,195) 156,506 366 156,872
Balance (in Shares) at Mar. 31, 2022 132,714          
Stock-based compensation 940 940 940
Exercise of options 10 10 10
Exercise of options (in Shares) 21          
Exercise of warrants 1 1 1
Exercise of warrants (in Shares) 222          
Net loss (74,604) (74,604) 3 (74,601)
Balance at Jun. 30, 2022 $ 214,652 $ (131,799) $ 82,853 $ 369 $ 83,222
Balance (in Shares) at Jun. 30, 2022 132,957          
[1] Periods presented have been adjusted to reflect the 1-for-10 reverse stock split on October 18, 2022 and the 1-for-20 reverse stock split on July 5, 2023. Additional information regarding the reverse stock splits may be found in Note 1 – Overview, Basis of Presentation and Significant Accounting Policies, included elsewhere in the notes to the condensed consolidated financial statements.